Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3070288 | 1.00 | NPC1 (0.33) | NPC1MEN1KMT2AGAAPOLB | |
| SCHEMBL3060253 | 0.92 | RAB9A (0.40) | NPC1GAAPOLBRAB9AKDM4E | |
| SCHEMBL3060249 | 0.92 | RAB9A (0.40) | NPC1GAAPOLBRAB9AKDM4E | |
| SCHEMBL3052839 | 0.82 | HTT (0.33) | NPC1MEN1KMT2AGAAPOLB | |
| SCHEMBL3052833 | 0.82 | HTT (0.33) | NPC1MEN1KMT2AGAAPOLB | |
| SCHEMBL3066491 | 0.80 | KDM4E (0.36) | NPC1KMT2AGAAKDM4EHTT | |
| SCHEMBL3062619 | 0.80 | KDM4E (0.35) | MEN1KMT2AKDM4EHTTALDH1A1 | |
| SCHEMBL3062622 | 0.80 | KDM4E (0.35) | MEN1KMT2AKDM4EHTTALDH1A1 | |
| SCHEMBL3066888 | 0.74 | RAB9A (0.36) | NPC1MEN1KMT2AGAAPOLB | |
| SCHEMBL3066884 | 0.74 | RAB9A (0.36) | NPC1MEN1KMT2AGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261719-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261719-A1 | CHEMICAL COMPOUNDS | NCOA3, NR4A3, NR0B2 | NPC1 639/4885MEN1 1245/4885KMT2A 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.